Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
229 hedge funds and large institutions have $1.62B invested in Sage Therapeutics in 2020 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 84 increasing their positions, 64 reducing their positions, and 84 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 64
7% more call options, than puts
Call options by funds: $14.8M | Put options by funds: $13.8M
0.35% more ownership
Funds ownership: 108.08% → 108.42% (+0.35%)
14% less funds holding
Funds holding: 266 → 229 (-37)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
40% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 84
60% less capital invested
Capital invested by funds: $4.04B → $1.62B (-$2.41B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$82.1M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$68.5M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$59.6M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$57.9M |
| 5 |
Morgan Stanley
New York
|
+$52.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$155M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$70.4M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$59.4M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$39.7M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$37.9M |
SAGE Hedge Fund Activity: Q1 2020 in Review
229 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2020, worth a combined $1.62B — down 60% from $4.04B a quarter earlier.
Sellers outnumbered buyers: 84 funds closed out of SAGE and 50 opened new positions — a net loss of 34 holders — while 64 trimmed existing stakes and 84 added.
The largest buyer was Victory Capital Management, adding an estimated $82.1M. The largest seller was T. Rowe Price Associates, cutting an estimated $155M.
- 229 institutional investors held Sage Therapeutics (SAGE) as of Q1 2020, down from 266 in Q4 2019.
- Funds reported $1.62B of Sage Therapeutics stock for Q1 2020, down 60% quarter-over-quarter.
- 50 funds opened new Sage Therapeutics positions in Q1 2020 and 84 closed out, a net change of -34 holders.
- The largest Sage Therapeutics buyer in Q1 2020 was Victory Capital Management, an estimated $82.1M added.
- The largest Sage Therapeutics seller in Q1 2020 was T. Rowe Price Associates, an estimated $155M sold.
Based on aggregated 13F filings for Q1 2020.